Phase I-II study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Dasatinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 26 May 2016 Status changed from discontinued to completed.
- 11 Jun 2014 Trial status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.